Clinical Spotlight on Metastatic Colorectal Cancer from the 2012 Gastrointestinal Cancer Meeting in San Francisco

Interview with Edith Mitchell

Activity Features

  • Expert Discussion
  • NewsFlash
  • Downloadable Slides

Activity Overview

prIME Oncology invites you to view an expert interview, eNewsflash, and downloadable slides regarding exciting new data released at the 2012 Annual Gastrointestinal Cancer Meeting in San Francisco.
This activity is restricted to healthcare providers based outside of the United States.
January 23

Colorectal Cancer

Alberto Sobrero, MD, Ospedale San Martino, Genova, Italy
Edith P. Mitchell, MD, FACP, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Featured Abstracts:
  • Results from VELOUR: A phase III study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer
  • Abstract #547: Observational study describing bevacizumab use and outcomes among metastatic colorectal cancer patients receiving care in the outpatient community in the United States
  • Abstract #561: Meta-analysis of anti VEGF class adverse events from 3 double-blind (Db) placebo (Pbo) controlled phase 3 trials with IV aflibercept
Learning Objectives:
Upon completion of this educational activity, participants should be able to:
  • Evaluate emerging clinical trial data pertaining to metastatic colorectal cancer, and evaluate how this data should be incorporated into current standards of care to improve patient outcomes
  • Discuss the rationale and utility of novel agents or combination strategies that may provide superior disease outcomes for patients with metastatic colorectal cancer compared to current standards of care

Continuing Education